Organtech
OrganTech is a Tokyo-based regenerative medicine company developing organ regeneration technologies including the Bio-hybrid Tooth dental implant, hair follicle regeneration therapy, and 3D artificial skin, serving dental clinics, alopecia patients, and pharmaceutical companies through clinical research and technology licensing.
- Company typePrivate
- Founded2023
- HeadquartersTokyo, Japan
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Organtech does
OrganTech, Inc. (株式会社オーガンテック) is a Tokyo-headquartered regenerative medicine company founded in 2008 by Professor Takashi Tsuji, built around the proprietary Organ Germ Method (器官原基法) developed in 2007. The technology reconstitutes functional organs by positioning epithelial and mesenchymal stem cells in a high-density compartmentalized 3D configuration, enabling regeneration of teeth, hair follicles, salivary glands, and lacrimal glands. The company operates three business lines: Bio-hybrid Tooth (a periodontal ligament-integrated dental implant), Hair Follicle Regeneration (a three-cell stem cell therapy for alopecia), and Three-dimensional Artificial Skin (a tension-loaded 3D skin model for pharmaceutical and cosmetics testing). All three programs rest on a single platform technology, with 37 patents (15 domestic, 22 international) and over 180 peer-reviewed publications in high-impact journals including Nature Communications, Scientific Reports, and Nature Protocols.
The company's revenue model is multi-pronged and still pre-commercial. Bio-hybrid Tooth is currently in a specified clinical research study at Minami Tohoku Medical Clinic (initiated February 2025, 4 patients enrolled, 3 evaluated at 24 weeks with successful osseointegration and no adverse events). Artificial skin technology is licensed to Kojima Bio for manufacturing and commercial sale to pharmaceutical, cosmetics, and healthcare companies. Hair follicle regeneration technology has been licensed domestically to an undisclosed Japanese partner for manufacturing rights, and research support services are provided to healthcare and medical enterprises. Pricing is not publicly disclosed across any segment. Target customer segments include dental clinics and oral healthcare providers, alopecia patients (the company cites 18 million androgenetic alopecia and 6 million telogen effluvium patients in Japan), pharmaceutical/cosmetics companies, and corporate R&D clients. QNova Inc. was engaged in August 2025 to pursue FDA 510(k) approval for the next-generation Bio-implant for US market entry.
Leadership transitioned in September 2024 with the appointment of Yoshio Shimo, former President and Chairman of Hino Motors (Toyota group), as Representative Director CEO, signaling a strategic pivot toward commercialization and international capital markets. CTO Miho Ogawa (PhD, biological engineering) and COO Yoshitake Yamaguchi (former Toshiba executive) round out the executive team. The company is venture-backed, having received investment from Kobayashi Pharmaceutical in February 2023 and completing an undisclosed fundraising round in June 2026 to support its next growth stage. The CEO has publicly stated NASDAQ listing as a future objective. The company targets the global dental implant market (~$4.9B in 2024, projected $8.4B by 2030 at ~10% CAGR) and the hair restoration market (projected to exceed $15B).
Organtech firmographics
Firmographics- Name
- Organtech
- Legal name
- 株式会社オーガンテック
- Website
- https://organ-tech.jp
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Short description
- OrganTech is a Tokyo-based regenerative medicine company developing organ regeneration technologies including the Bio-hybrid Tooth dental implant, hair follicle regeneration therapy, and 3D artificial skin, serving dental clinics, alopecia patients, and pharmaceutical companies through clinical research and technology licensing.
- Ownership category
- akta.pro rank
Organtech industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- 3D Bioprinting & Biofabrication (HLAAAGAC), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Organtech is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Organtech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Bio-hybrid Tooth (Dental Implant) Products and Services: Revenue from periodontal ligament-integrated dental implants (Bio-hybrid Tooth) targeting dental clinics and hospitals. Currently in clinical research stage with a specific clinical study initiated in February 2025 at Minami Tohoku Medical Clinic. Revenue model involves medical device manufacturing and sales, and clinical service fees.
- Artificial Skin Licensing and Research Services: Revenue from licensing tension-providing 3D artificial skin manufacturing technology to pharmaceutical, cosmetics, and healthcare companies for drug safety testing, efficacy screening, and disease model development. Research support services for hair care and hair loss product development using human dermal papilla cells are also provided.
- Hair Follicle Regeneration Technology Licensing: Revenue from licensing domestic manufacturing rights for hair follicle cell-derived components including the third cell type (hair follicle regeneration-supporting cells), targeting alopecia treatment applications. Clinical translation strategy is ongoing toward hair restoration therapies.
- Research Support Services: Corporate research and development support services leveraging OrganTech's extensive life sciences expertise, covering healthcare and medical domains. Services include artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support, and general healthcare product development consulting.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Organtech product offering
Product offeringCore offering
OrganTech develops and commercializes proprietary organ regeneration technologies built on its foundational Organ Germ Method (器官原基法), a 3D stem cell manipulation technique. Its commercial portfolio consists of three product lines: Bio-hybrid Tooth (periodontal ligament-integrated dental implants), Hair Follicle Regeneration therapy using a three-cell configuration, and tension-providing 3D Artificial Skin models for pharmaceutical and cosmetics testing. The company also offers research support and licensing services to corporate R&D clients in healthcare and life sciences.
Product overview
OrganTech is a regenerative medicine company developing three core product lines based on its world-first organ regeneration technology: Bio-hybrid Tooth (dental implant with periodontal ligament), Hair Follicle Regeneration (hair loss treatment using stem cells), and Three-dimensional Artificial Skin (tension-loaded skin model for testing). The company operates as a platform of technologies anchored by the 'Organ Germ Method' developed in 2007, with all three products addressing quality of life (QOL) medical needs.
Differentiator
Problem solved
Functional benefit
Products and services
- Bio-hybrid Tooth (バイオハイブリッドトゥース) A next-generation dental implant integrating a hydroxyapatite-coated titanium fixture with a regenerated periodontal ligament (periodontal ligament, cementum, and alveolar bone) derived from the patient's own residual tissue. It restores natural physiological tooth functions including shock absorption, proprioception, and immune defense that are absent in conventional osseointegration implants. Targeted at dental clinics, oral surgeons, and prosthodontists.
- Hair Follicle Regeneration (毛髪再生) A regenerative therapy that reconstitutes functional hair follicles from a three-cell configuration: epithelial stem cells, mesenchymal dermal papilla cells, and a newly identified accessory mesenchymal cell (hair follicle regeneration-supporting cell) derived from the patient's own occipital hair. Designed for alopecia treatment including androgenetic alopecia, female pattern hair loss, alopecia areata, cicatricial alopecia, and drug-induced alopecia.
- Three-dimensional Artificial Skin (三次元人工皮膚) The world's first 3D artificial skin model with applied mechanical tension, where epidermal and dermal cell orientation mimics natural skin and dramatically enhances cellular physiological function. Licensed to pharmaceutical, cosmetics, and healthcare companies for safety testing (skin irritation assays), high-sensitivity functional assays, mechanism analysis, and disease/damage model development.
- Research Support Services (研究支援) Contract research and development services for corporate clients in healthcare and medical domains. Includes artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support using human dermal papilla cells, and general healthcare product development consulting leveraging OrganTech's life sciences expertise.
Quantifiable outcome
- Osseointegration confirmed in all 4 enrolled patients; 3 evaluated at 24 weeks showed natural tooth-like test values and no inflammatory adverse events (periotest values within natural tooth range of 2-5)
- +3 more outcomes
Companies that use Organtech
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Organtech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Organtech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, core and major.
- MID-G (Medical Innovation and Dental Growth)minorOrganTech became a supporting member of MID-G, an organization that supports dental clinics in academic, educational, and business management areas. This partnership supports the company's Bio-hybrid Tooth go-to-market strategy.
- RIKEN Center for Biosystems Dynamics Research (理化学研究所 生命機能科学研究センター)coreA long-standing research collaboration with RIKEN BDR, where OrganTech's founder Takashi Tsuji led the Organ Induction Research Team from 2014-2024. Joint research has produced the Organ Germ Method and multiple organ regeneration breakthroughs including the discovery of the accessory mesenchymal cell essential for hair follicle regeneration, published in Biochemical and Biophysical Research Communications in 2026.
- Kojima Bio Co., Ltd. (コージンバイオ社)majorLicensing agreement for three-dimensional artificial skin technology with Kojima Bio Co., Ltd., enabling the company to manufacture and commercialize OrganTech's tension-providing 3D artificial skin for pharmaceutical, cosmetics, and healthcare applications.
- QNova Inc.corePartnership with US-based QNova Inc. to advance next-generation Bio-implant toward FDA regulatory approval and US market entry. QNova provides regulatory expertise and market access support for the FDA 510(k) pathway as a medical device.
- Hillside Akasaka Dental Clinic (ヒルサイド赤坂デンタルクリニック)majorClinical research site for next-generation Bio-implant in Tokyo, initiated August 2025 as part of OrganTech's multi-site clinical development strategy.
- Undisclosed Japanese Partner (国内ライセンス先)majorDomestic manufacturing rights license for hair follicle cell-derived components including the third 'hair follicle regeneration-supporting' cell type for alopecia treatment applications.
- Musashi Precision Co., Ltd. (武蔵精密工業株式会社)majorBusiness partnership for joint R&D of automated manufacturing equipment for 3D artificial skin models. Musashi Precision contributes manufacturing automation expertise while OrganTech provides the artificial skin technology platform.
- Minami Tohoku Medical Clinic / Brain Surgery Disease General Institute (南東北医療クリニック / 脳神経疾患研究所附属総合南東北病院)coreClinical research partnership for Bio-hybrid Tooth specified clinical study. Responsible physician Dr. Shohei Kasugai (formerly Tokyo Medical and Dental University) leads the study. The clinic conducted patient enrollment (completed October 2025) and reported positive interim results at 24-week evaluation for all 3 assessed patients.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Organtech competitors and assessment
Company assessmentDirect peers
- Cyfuse Biomedical: Japanese 3D bioprinting company developing tissue-engineered products using its proprietary Kenzan method. Direct peer to OrganTech in 3D tissue engineering and biofabrication, with overlap in regenerative medicine product development in Japan.
- J-TEC (Japan Tissue Engineering Co., Ltd.): Japanese regenerative medicine company commercializing autologous tissue-engineered products (cartilage, skin, cornea). Direct peer in the regenerative medicine/QOL product space, sharing the same Japanese regulatory environment and commercialization model via cell-based therapies.
- Organovo Holdings: US-based 3D bioprinting company developing human tissue models for drug discovery and therapeutic applications. Comparable to OrganTech's 3D Artificial Skin program, both leveraging biofabrication to create human-relevant tissue models for pharma and cosmetics testing.
- Stemson Therapeutics: US-based biotech developing iPSC-derived hair follicle regeneration therapies for androgenetic alopecia. Directly comparable to OrganTech's Hair Follicle Regeneration program as both pursue cellular regeneration of hair follicles rather than transplantation or drugs.
- Toregem BioPharma: A Japanese clinical-stage biotech developing tooth regeneration therapies using anti-USAG-1 antibody technology. Directly comparable to OrganTech as one of very few companies globally pursuing biological tooth regeneration, with overlapping target patient populations and similar pre-commercial stage.
- CellSeed: Japanese regenerative medicine company developing temperature-responsive cell cultureware and epithelial sheet products for regenerative applications. Comparable to OrganTech as a Japan-based regenerative medicine company pursuing cell-based tissue products in adjacent regenerative indications.
Broad incumbents
- Straumann Group: Global leader in dental implants and restorative dentistry with extensive surgeon training, distribution, and brand recognition. Relevant broad incumbent in the dental implant market that OrganTech's Bio-hybrid Tooth would need to displace or differentiate against upon commercialization.
- MiMedx Group: US-listed regenerative medicine company commercializing placental tissue allografts for wound healing and surgical recovery. Comparable to OrganTech as a broad regenerative medicine commercializer, though focused on a different tissue modality and existing US commercial scale.
- Integra LifeSciences: Global medical device company with broad regenerative technology and tissue products portfolio including dermal regeneration templates. Comparable as a broad incumbent offering overlapping regenerative skin/tissue solutions, though at much larger scale and via different (scaffold-based) technology.
Emerging players
- Medipost: Korean stem cell therapeutics company commercializing Cartistem and other umbilical cord blood-derived stem cell products. Comparable to OrganTech as an Asian stem cell therapeutics developer with both regenerative and tissue-engineering programs targeting similar QOL indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Organtech social profiles
Digital presenceOrgantech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Organtech leadership team
Management profileNumber of profiles
Profiles4 records
Organtech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Organtech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Organtech
What does Organtech do?
OrganTech develops and commercializes proprietary organ regeneration technologies built on its foundational Organ Germ Method (器官原基法), a 3D stem cell manipulation technique. Its commercial portfolio consists of three product lines: Bio-hybrid Tooth (periodontal ligament-integrated dental implants), Hair Follicle Regeneration therapy using a three-cell configuration, and tension-providing 3D Artificial Skin models for pharmaceutical and cosmetics testing. The company also offers research support and licensing services to corporate R&D clients in healthcare and life sciences.
Is Organtech a public or private company?
Organtech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Organtech founded?
Organtech was founded in 2023.
Where is Organtech based?
Organtech is headquartered in Tokyo, Japan, in the Asia region.
How does Organtech make money?
Four revenue lines are on record. Bio-hybrid Tooth (Dental Implant) Products and Services are the primary driver. The others are artificial Skin Licensing and Research Services, hair Follicle Regeneration Technology Licensing and research Support Services.
Who are Organtech's main competitors?
Direct peers on record are Cyfuse Biomedical, J-TEC (Japan Tissue Engineering Co., Ltd.), Organovo Holdings, Stemson Therapeutics, Toregem BioPharma and CellSeed. Broad incumbents are Straumann Group, MiMedx Group and Integra LifeSciences. Medipost is listed as an emerging player.
Does Organtech have an API?
No public API is recorded for Organtech.
What industry is Organtech in?
Organtech's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 325414 and its SIC code is 2836.